Disease Overview：Lupus Erythematosus（SLE）
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder characterized by loss of immune tolerance to nuclear antigens, leading to widespread inflammation and tissue damage. While it can affect multiple organs—including kidneys, joints, hematopoietic system, and central nervous system—cutaneous manifestations are among the most common and visible features. These include malar rash, discoid lesions, photosensitivity, oral ulcers, and subacute cutaneous lupus erythematosus (SCLE), often requiring coordinated dermatologic and rheumatologic management. Diagnosis relies on clinical criteria (e.g., ACR/EULAR 2019 classification) combined with serologic markers such as antinuclear antibodies (ANA), anti-dsDNA, and anti-Smith antibodies. Treatment aims to control disease activity, prevent flares, minimize organ damage, and improve quality of life—using hydroxychloroquine as first-line therapy, supplemented by corticosteroids, immunosuppressants (e.g., mycophenolate mofetil, azathioprine), and newer biologics like belimumab.
China offers distinct advantages for SLE dermatologic care: its tertiary hospitals house nationally certified lupus specialty centers with multidisciplinary teams experienced in complex cutaneous and systemic presentations. Advanced diagnostic tools—including confocal laser scanning microscopy and high-sensitivity autoantibody profiling—are widely available. Clinical outcomes reflect robust real-world evidence: over 85% of patients achieve low disease activity (LLDAS criteria) within 12 months under standardized protocols. Compared to treatment in the US or Western Europe, costs for comprehensive care—including biologics, monitoring, and follow-up—are typically 40–60% lower, without compromising efficacy or safety standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital accreditation, coordinating appointments with SLE-dedicated dermatologists, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and translation services to post-treatment rehabilitation planning.
Lupus Erythematosus: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Cutaneous Lupus Erythematosus (CLE)
Non-Surgical / Conservative / Medication-Based Management
*Target Criteria:* Confirmed diagnosis of discoid (DLE), subacute (SCLE), or tumid lupus; mild-to-moderate skin involvement without systemic organ damage.
- •Topical Therapy
- *Calcineurin inhibitors (tacrolimus 0.1% ointment, 15g)*: ¥260–¥320 → $36–$45
- •Systemic Medications
- *Low-dose prednisone (5 mg × 30 tablets)*: ¥25–¥40 → $3.50–$5.60 - *Methotrexate (2.5 mg × 20 tablets)*: ¥110–¥150 → $15–$21
- •Diagnostic & Monitoring Fees (Per Episode)
- *ANA/ENA panel (immunoblot)*: ¥320–¥410 → $45–$57 - *Complete blood count + liver/kidney function*: ¥180–¥240 → $25–$34
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Refractory, hypertrophic, or scarring DLE lesions unresponsive to ≥6 months of systemic therapy; no active systemic inflammation or cytopenia.
- •Laser Ablation (Pulsed Dye or Fractional CO₂)
- *Full-face treatment (≥3 sessions recommended)*: ¥5,200–¥7,800 → $720–$1,080
- •Surgical Excision + Primary Closure
- •Preoperative Workup (Mandatory)
- *Pre-op dermatologic assessment + lesion mapping*: ¥220–¥300 → $30–$42
Special / Complex Condition Management
- •*Bullous or verrucous CLE with extensive scarring*:
- •*Drug-induced CLE requiring rapid de-escalation*:
- •*Pediatric CLE (<12 years)*:
Quick Selection Guide
- •Young adult (18–35), mild DLE, budget < $200/year: Start with hydroxychloroquine + topical clobetasol ($13–$17/year medication cost).
- •Middle-aged (40–60), chronic SCLE with photosensitivity & comorbid hypertension: Hydroxychloroquine + low-dose prednisone + strict photoprotection ($18–$23/year meds); avoid methotrexate if renal impairment present.
- •Elderly (>70), hypertrophic DLE on ear/scalp, limited mobility: Fractional CO₂ laser (1–2 sessions) + tacrolimus maintenance ($360–$720 total) — avoids long-term steroid risks.
- •Severe, refractory tumid CLE with cosmetic disfigurement: Rituximab-based regimen ($1,730–$2,200) only after confirming absence of infection and normal IgG levels.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Lupus Erythematosus Medical Vacation Packages
Curated transparent all-inclusive packages combining Lupus Erythematosus treatment with China top medical destinations:
